BCL-2 is short for B lymphoblastoma-2 gene, a proto-oncogene. As a proto-oncogene, BCL-2 gene has the effect of inhibiting apoptosis, which is closely related to the occurrence of cancer. Simply put, after dividing a certain number of times, normal cells will apoptose under the action of a series of regulatory factors, such as proto-oncogenes and inhibitory oncogenes, and the overexpression of the BCL-2 gene has tumorigenic effects. According to research, BCL-2 gene translocation is seen in 85% of follicular lymphomas with specificity. The World Health Organization defined lymphoma classification in 2016 as a double or triple hit lymphoma when B-cell lymphomas have BCL-2 and C-MYC or BCL-6 gene rearrangements, are highly aggressive, karyotypically complex, and have a range of pathomorphologic features, are highly malignant, and have a poor prognosis. Simply put, it means that if BCL-2 gene translocation is seen in lymphoma, it signifies a higher degree of malignancy of the tumor, which is more difficult to be cured and has a poorer prognosis. In addition to lymphoma, the expression of BCL-2 gene is also closely related to other malignant tumors. It is recommended that patients should consult the doctor in time, and should not be negligent to avoid delaying the condition.